Catalogue

Background
A central concept in tumor immunology is that malignancies bear tumor associated antigens, which are not or to a much lesser degree found in normal tissues. These antigens can be used as distinctive markers in diagnosis and therapy. As a consequence, monoclonal antibodies to such antigens may represent useful tools for histopathology, immunoscintigraphy and for immunotherapy.

Source
OVTL16 is a Mouse monoclonal IgG1 antibody derived by fusion of SP2/0 Mouse myeloma cells with spleen cells from a BALB/c Mouse immunized with cyst fluid, obtained from a patient with a poorly differentiated Human ovarian carcinoma.

Product
Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.

Specificity
OVTL16 recognizes a conformational epitope on ovarian carcinoma membrane antigen OA3 which is present in ovarian carcinomas and in cyst fluids obtained from these carcinomas, as well as in oviductal carcinomas and some endometrial carcinomas

Applications
OVTL16 is suitable for immunohistochemistry on frozen tissues and for staining with avidin-biotinylated Horseradish peroxidase complex (ABC) as detection reagent. Optimal antibody dilution should be determined by titration

Storage
The antibody is shipped at ambient temperature and may be stored at +4°C. For prolonged storage prepare appropriate aliquots and store at or below -20°C. Prior to use, an aliquot is thawed slowly in the dark at ambient temperature, spun down again and used to prepare working dilutions by adding sterile phosphate buffered saline (PBS, pH 7.2). Repeated thawing and freezing should be avoided. Working dilutions should be stored at +4°C, not refrozen, and preferably used the same day. If a slight precipitation occurs upon storage, this should be removed by centrifugation. It will not affect the performance or the concentration of the product.

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
Boerman, O., Makkink, K., Massuger, L., Thomas, C., Kenemans, P., Hanselaar, T., and Poels, L. (1989). Monoclonal antibodies anti ovarian carcinoma-associated antigens, raised by immunization with cyst fluids, Anticancer Res 9, 551-8 Boerman, O., Massuger, L., Makkink, K., Thomas, C., Kenemans, P., and Poels, L. (1990). Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. Anticancer Res 10, 1289-1295. van Niekerk, C. C., Ramaekers, F. C., Hanselaar, A. G., Aldeweireldt, J., and Poels, L. G. (1993). Changes in expression of differentiation markers between normal ovarian cells and derived tumors, Am J Pathol 142, 157-77. Slobbe, R., Poels, L., ten Dam, G., Boerman, O., Nieland, L., Leunissen, J., Ramaekers, F., and van Eys, G. (1994). Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences, Clin Exp Immunol 98, 95-103. van Niekerk, C. C., Vooijs, P., Casparie-van Velsen, I. J., and Poels, L. G. (1997). Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies. Cancer Detect Prev 21, 247-257.

Safety Datasheet(s) for this product: